» Articles » PMID: 10334143

Antifungal Prophylaxis During the Early Postoperative Period of Lung Transplantation. Valencia Lung Transplant Group

Overview
Journal Chest
Publisher Elsevier
Specialty Pulmonary Medicine
Date 1999 May 20
PMID 10334143
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Fungal infections occur frequently in lung transplant patients, with the highest risk being in the early postoperative period (the initial hospitalization after lung transplantation). Aspergillus is responsible for more than half of all fungal infections, and Aspergillus has even been considered a contraindication for lung transplantation because of its difficult therapy and frequently fatal outcome. The aim of this article is to evaluate the success of an antifungal prophylaxis protocol to prevent fungal infection in the immediate postoperative period in lung transplant recipients.

Material And Methods: From March 1994 to March 1997, we performed 52 lung transplants in 31 men and 21 women who received antifungal prophylaxis with fluconazole, 400 mg/d, and aerosolized amphotericin B, 0.6 mg/kg/d, during the postoperative period.

Results: The mean (+/- SD) postoperative period duration was 49 +/- 27.5 days. No fungal infections were observed during this period, and all patients provided negative cultures. We also found no toxicity related to antifungal drugs. The dose of cyclosporine was easily adjusted in every recipient according to blood levels so that effective immunosuppression was not compromised.

Discussion: In our study, the removal of the lungs and antifungal prophylaxis with fluconazole and aerosolized amphotericin B prevented fungal infection in the postoperative period in all 52 lung transplant recipients.

Citing Articles

Novel antifungals and treatment approaches to tackle resistance and improve outcomes of invasive fungal disease.

Hoenigl M, Arastehfar A, Arendrup M, Bruggemann R, Carvalho A, Chiller T Clin Microbiol Rev. 2024; 37(2):e0007423.

PMID: 38602408 PMC: 11237431. DOI: 10.1128/cmr.00074-23.


Could the Lung Be a Gateway for Amphotericin B to Attack the Army of Fungi?.

Patricio B, da Silva Lopes Pereira J, Sarcinelli M, de Moraes B, Rocha H, Goncalves-de-Albuquerque C Pharmaceutics. 2022; 14(12).

PMID: 36559201 PMC: 9784761. DOI: 10.3390/pharmaceutics14122707.


Inhaled Antifungal Agents for Treatment and Prophylaxis of Bronchopulmonary Invasive Mold Infections.

Brunet K, Martellosio J, Tewes F, Marchand S, Rammaert B Pharmaceutics. 2022; 14(3).

PMID: 35336015 PMC: 8949245. DOI: 10.3390/pharmaceutics14030641.


Conventional Antifungals for Invasive Infections Delivered by Unconventional Methods; Aerosols, Irrigants, Directed Injections and Impregnated Cement.

Drew R, Perfect J J Fungi (Basel). 2022; 8(2).

PMID: 35205966 PMC: 8879564. DOI: 10.3390/jof8020212.


Strategies for the Prevention of Invasive Fungal Infections after Lung Transplant.

Bitterman R, Marinelli T, Husain S J Fungi (Basel). 2021; 7(2).

PMID: 33562370 PMC: 7914704. DOI: 10.3390/jof7020122.